---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-023428"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:30:14.910395+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outset Medical receives FDA 510(k) clearance for next-generation Tablo dialysis system; Q2 2026 launch

## Summary
- FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.
- Tablo is first dialysis system to meet FDA's most rigorous cybersecurity guidance (June 2025).
- Hardware, operating system, and software enhancements improve reliability and user experience.
- Shipping to customers expected to begin in Q2 2026; current users eligible to upgrade.
- CEO Leslie Trigg highlights milestone as reflecting commitment to innovation and patient safety.

## SEC filing metadata
- accession: 0001193125-26-023428
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000119312526023428/0001193125-26-023428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000119312526023428/om-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-023428
- JSON: https://secwatch.observer/filing/0001193125-26-023428.json
- Plain text: https://secwatch.observer/filing/0001193125-26-023428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.